These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
826 related articles for article (PubMed ID: 11509935)
1. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935 [TBL] [Abstract][Full Text] [Related]
2. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752 [TBL] [Abstract][Full Text] [Related]
3. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881 [TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160 [TBL] [Abstract][Full Text] [Related]
5. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307 [TBL] [Abstract][Full Text] [Related]
6. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532 [TBL] [Abstract][Full Text] [Related]
8. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle. Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients. Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605 [TBL] [Abstract][Full Text] [Related]
12. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213 [TBL] [Abstract][Full Text] [Related]
13. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174 [TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG; N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087 [TBL] [Abstract][Full Text] [Related]
15. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Myers SE; Mick R; Williams SF Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470 [TBL] [Abstract][Full Text] [Related]
17. [Intensive chemotherapy in the treatment of patients with metastatic breast cancer]. Salgado JE; Aramendía JM; Fernández-Hidalgo OA; Lozano E; Rebollo J; Martínez-Monge R; Subirá ML; Brugarolas A Rev Med Univ Navarra; 1997; 41(3):143-51. PubMed ID: 10420919 [TBL] [Abstract][Full Text] [Related]
18. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556 [TBL] [Abstract][Full Text] [Related]
19. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S Breast J; 2006; 12(6):531-5. PubMed ID: 17238982 [TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study. Toh HC; McAfee SL; Sackstein R; Multani P; Cox BF; Garcia-Carbonero R; Colby C; Spitzer TR Bone Marrow Transplant; 2000 Jan; 25(1):19-24. PubMed ID: 10654009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]